利拉利汀联合二甲双胍治疗2型糖尿病有效性和安全性的Meta分析

发布时间：2018-02-05 22:17

本文关键词： 利拉利汀二甲双胍糖尿病 2型 Meta分析随机对照试验　出处：《新疆医科大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的：评价利拉利汀联合二甲双胍治疗2型糖尿病的疗效和安全性。方法：计算机检索相关期刊论文、万方数据库、维普数据库、Plumped、ISI Web of Science和Debase数据库,筛选出利拉利汀治疗2型糖尿病的所有随机对照试验(RCTs),采用RevMan5.1软件包进行Meta分析,比较利拉利汀联合二甲双胍(试验组)或安慰剂联用及单用二甲双胍(对照组)治疗对2型糖尿病患者糖化血红蛋白(HbA1c)和空腹血糖(FPG)水平的影响,并比较低血糖发生率。结果：共检出中英文文献725篇,经筛选最终纳入4项RCTs研究,共2036例患者。在降低患者HbA1c水平方面,试验组(利拉利汀2.5mg,bid)明显优于对照组[标准化平均差(SMD)=-7.47,95%置信区间(CI)：-10.37～-4.58,P0.001],而试验组(利拉利汀5mg.qd)与对照组相比无显著意义[SMD=-9.13,95% CI:-18.86～-0.60,P0.001]。在降低患者FPG水平方面,试验组的治疗效果明显优于对照组(SMD=-6.00,95% CI:-8.82々-3.91, P0.001)。在安全性方面,试验组(利拉利汀2.5mg,bid)与对照组患者的低血糖发生率差异无显著意义[相对危险系数(RR)=0.94,95%CI:0.16～5.50, P=0.94],而试验组(利拉利汀5mg.qd)与对照组患者的低血糖发生率差异有显著意义(RR=0.24,95%CI:0.07～0.80, P=0.02)。结论：利拉利汀联合二甲双胍治疗能有效降低2型糖尿病患者的HbA1c和FPG水平,且安全性较好,因本研究异质性高,需进一步研究证实。但是长期用药的有效性和安全性仍缺乏足够证据。
[Abstract]:Objective: To evaluate the efficacy and safety of Leigh Larry Dean and metformin in treatment of type 2 diabetes. Methods: computer retrieval Chinese CNKI, Wanfang database, VIP database, Plumped ISI, Web of and Science Debase database, selected Leigh Larry Dean in the treatment of all randomized controlled trials of type 2 diabetes mellitus (RCTs), packet analysis was performed by Meta RevMan5.1 software, Leigh Larry Dean (experimental group) and metformin combined with metformin alone or placebo (control group) for treatment of patient with type 2 diabetes (HbA1c) and fasting blood glucose (FPG) levels, and compare the incidence of hypoglycemia. Results: there were 725 literatures in English, selected into the 4 RCTs study, a total of 2036 cases of patients. To reduce the level of HbA1c in patients with experimental group (Leigh Larry Dean, 2.5mg, bid) was significantly better than the control group [standardized mean difference (SMD =) 7.47,95% confidence interval (CI):-10.37 ~ -4.58, P0.001], and the test group (Leigh Larry Dean 5mg.qd) compared with the control group no significant [SMD=-9.13,95% CI:-18.86 to -0.60 P0.001]. in reducing the level of FPG were significantly better than the therapeutic effect of the experimental group (control group SMD= -6.00,95% CI:-8.82 has -3.91, P0.001). In the aspect of safety, testing (Leigh Larry Dean 2.5mg, bid group) and the control group of patients with hypoglycemia rate showed no significant difference [relative risk coefficient (RR) =0.94,95%CI:0.16 ~ 5.50, P=0.94], and the test group (Leigh Larry Dean 5mg.qd) and the control group of patients with hypoglycemia rate had significant difference (RR=0.24,95%CI:0.07 ~ 0.80, P=0.02). Conclusion: Leigh Larry Dean combined with metformin the treatment can effectively reduce the patients with type 2 diabetes HbA1c and FPG levels, and the security is good, because of the heterogeneity of high, but the long-term need for further studies. There is still a lack of sufficient evidence for the effectiveness and safety of the drug.

【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R587.1

【相似文献】